Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 18/20 | 0.74 |
| ▸ | KDR | P35968 | 2/20 | 0.72 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.72 |
| ▸ | MUSK | O15146 | 1/20 | 0.72 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.72 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.72 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.72 |
| ▸ | PAK3 | O75914 | 1/20 | 0.72 |
| ▸ | STK10 | O94804 | 1/20 | 0.72 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.72 |
| ▸ | ABL1 | P00519 | 1/20 | 0.72 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.72 |
| ▸ | LCK | P06239 | 1/20 | 0.72 |
| ▸ | CSF1R | P07333 | 1/20 | 0.72 |
| ▸ | YES1 | P07947 | 1/20 | 0.72 |
| ▸ | LYN | P07948 | 1/20 | 0.72 |
| ▸ | RET | P07949 | 1/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.72 |
| ▸ | KIT | P10721 | 1/20 | 0.72 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18409100 | 0.99 | FLT3 (0.73) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL474761 | 0.93 | FLT3 (0.73) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL12647827 | 0.93 | FLT3 (0.83) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Hydrochloric Acid SCHEMBL18409101 | 0.93 | FLT3 (0.72) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL3452945 | 0.89 | FLT3 (0.65) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL1758963 | 0.89 | FLT3 (0.59) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL18699843 | 0.88 | FLT3 (0.78) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL20434978 | 0.88 | APP (0.71) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL74706 | 0.88 | FLT3 (0.82) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL74009 | 0.87 | FLT3 (0.65) | FLT3KDRBMPR1BMUSKEPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119925616-A | CD20 therapy, CD22 therapy and combination therapy with CD19 Chimeric Antigen Receptor (CAR) expressing cells | 诺华股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119923398-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-111630054-B | Substituted pyrazolo [3,4-d ] pyrimidine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-111615514-B | Substituted pyrazolo [4,3-C ] pyridine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2022-10-11 | — | — | CN | disclosed |
| US-8883783-B2 | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith | AMBIT BIOSCIENCES CORPORATION (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2429524-A1 | METHODS OF TREATING PROLIFERATIVE DISEASES | Ambit Biosciences Corporation (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2410987-A1 | METHODS OF TREATMENT USING COMBINATION THERAPY | Ambit Biosciences Corporation (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2011056764-A1 | ISOTOPICALLY ENRICHED OR FLUORINATED IMIDAZO[2,1-B][1,3]BENZOTHIAZOLES | AMBIT BIOSCIENCES CORP. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2010132787-A1 | METHODS OF TREATING PROLIFERATIVE DISEASES | AMBIT BIOSCIENCES CORPORATION (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-2205244-A1 | METHODS OF ADMINISTERING N-(5-TERT-BUTYL-ISOXAZOL-3-YL)-N'-{4-Ý7-(2-MORPHOLIN-4-YL-ETHOXY)IMIDAZOÝ2,1-B¨Ý1,3¨BENZOTHIAZOL-2-YL¨PHENYL}UREA TO TREAT PROLIFERATIVE DISEASE | Ambit Biosciences Corporation (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-2201018-A2 | SOLID FORMS COMPRISING N-(5-TERT-BUTYL-ISOXAZOL-3-YL)-N'-{4-Ý7-(2-MORPHOLIN-4-YL-ETHOXY)IMIDAZOÝ2,1-B¨Ý1,3¨BENZOTHIAZOL-2-YL¨PHENYL}UREA, COMPOSITIONS THEREOF, AND USES THEREWITH | Ambit Biosciences Corporation (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090131426-A1 | SOLID FORMS COMPRISING N-(5-TERT-BUTYL-ISOXAZOL-3-YL)-N'-UREA, COMPOSITIONS THEREOF, AND USES THEREWITH | AMBIT BIOSCIENCES | 2009-05-21 | — | — | US | disclosed |
| WO-2009061446-A1 | METHODS OF ADMINISTERING N-(5-TERT-BUTYL-ISOXAZOL-3-YL)-N'-{4-[7-(2-MORPHOLIN-4-YL-ETHOXY)IMIDAZO[2,1-B][1,3]BENZOTHIAZOL-2-YL]PHENYL}UREA TO TREAT PROLIFERATIVE DISEASE | AMBIT BIOSCIENCES CORP. (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009038757-A2 | SOLID FORMS COMPRISING N-(5-TERT-BUTYL-ISOXAZOL-3-YL)-N'-{4-[7-(2-MORPHOLIN-4-YL-ETHOXY)IMIDAZO[2,1-B][1,3]BENZOTHIAZOL-2-YL]PHENYL}UREA, COMPOSITIONS THEREOF, AND USES THEREWITH | AMBIT BIOSCIENCES CORPORATION (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131426-A1 | SOLID FORMS COMPRISING N-(5-TERT-BUTYL-ISOXAZOL-3-YL)-N'-UREA, COMPOSITIONS THEREOF, AND USES THEREWITH | OAT, TERT, TPMT | FLT3 797/4885KDR 4676/4885BMPR1B 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.